source
- Capricor's Duchenne therapy is rejected again, as FDA cites significant issues with trialCapricor Therapeutics’ deramiocel cell therapy was rejected for a second time by the FDA on Friday, despite the company's pivot to a narrower indication within Duchenne muscular dystrophy. In aEndpoints · 1h ago↗ source
- RevMed's Rasonque shows strong first-line response and survival benefit in early pancreatic cancer dataRevMed reported early-stage results from its open‑label Phase 1/2 RMC‑GI‑102 trial, presented at the EORTC‑N conference, evaluating Rasonque combined with chemotherapy in patients with first‑line m…